Home
Safe Snack Guide
Peanut and Tree Nut Free Edition
Milk Free Edition
Sesame Free Edition
Gluten Free Edition
Custom Edition
Allergence
Coupons
About Us
SnackSafely.com Media Kit
SnackSafely.com Advertising Guide
Subscribe to our newsletter
Contact Us
Resources
FAQ
Partner Manufacturers
Tools for Schools
Coupons
Inspiring Food Allergy Bloggers and Authors
Search
Home
Safe Snack Guide
Peanut and Tree Nut Free Edition
Milk Free Edition
Sesame Free Edition
Gluten Free Edition
Custom Edition
Allergence
Coupons
About Us
SnackSafely.com Media Kit
SnackSafely.com Advertising Guide
Subscribe to our newsletter
Contact Us
Resources
FAQ
Partner Manufacturers
Tools for Schools
Coupons
Inspiring Food Allergy Bloggers and Authors
Search
Tag: Daniel Tassé
Viaskin Peanut Patch Therapy Delayed Further as DBV Readies Another Phase...
Dave Bloom
-
2021/12/22
The patch therapy remains in regulatory limbo.
FDA Wants More Viaskin Peanut Data Resulting in Further Approval Delays
Dave Bloom
-
2021/10/27
Delays mount pushing trials of modified patch.
DBV, Developers of Patch Therapies for Allergies to Peanuts, Milk and...
Dave Bloom
-
2021/01/08
The company announced they would be laying off 200 employees in Q1.
FDA Denies Approval of Viaskin Peanut “Patch” Therapy
Dave Bloom
-
2020/08/04
The FDA raised concerns that adhesion of the patch would affect the efficacy of the therapy.
Will the Viaskin “Patch” Therapy for Peanut Allergy be Approved Soon?...
Dave Bloom
-
2020/06/30
Company is restructuring in anticipation of delays.
FDA Has Questions About Viaskin Peanut Efficacy, Delays Meeting with DBV...
Dave Bloom
-
2020/03/17
The company warned the FDA's target date for their decision on approval could be delayed.
FDA Advisory Committee Meeting to Review Viaskin Peanut for the Treatment...
News Wire ~ 3rd Party Press Release
-
2020/02/22
Next step in the approval process for the therapy scheduled for May 15, 2020.
DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut...
News Wire ~ 3rd Party Press Release
-
2019/10/04
If approved, Viaskin Peanut would be the first and only epicutaneous immunotherapy indicated for this potentially life-threatening condition in children.
DBV Technologies Submits Biologics License Application to FDA for Viaskin Peanut...
News Wire ~ 3rd Party Press Release
-
2019/08/08
This submission addresses the additional data needed on manufacturing procedures and quality controls which were communicated by the FDA in December.
DBV to Resubmit Application to FDA for Viaskin Peanut Approval in...
News Wire ~ 3rd Party Press Release
-
2019/02/14
Company allays concerns that BLA would not be resubmitted.
1
2
Page 1 of 2